image header

News Releases

News Releases

Sep 21, 2022

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference Read more

Sep 1, 2022

ALX Oncology Announces Upcoming Investor Conference Participation Read more

Aug 15, 2022

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer Read more

Aug 11, 2022

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer Read more

Aug 8, 2022

ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Read more

Aug 1, 2022

ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma Read more

Jun 29, 2022

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia Read more

Jun 3, 2022

ALX Oncology Announces Evorpacept Clinical Program Updates Read more

Jun 1, 2022

ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference Read more

May 9, 2022

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Read more

Displaying 1 - 10 of 16